SCHEMBL2880202

SCHEMBL2880202

CCn1c(-c2ccc(N)cc2)c(C#N)c2ccc(N3CCN(C)CC3)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
ADRA2C P18825 3/20 0.44
GAA P10253 3/20 0.44
MAPT P10636 3/20 0.44
GFER P55789 2/20 0.44
PTK2B Q14289 2/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
ESR2 Q92731 1/20 0.44
KHK P50053 2/20 0.40
HRH4 Q9H3N8 5/20 0.39
HTR2A P28223 2/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
HTR1D P28221 1/20 0.39
HTR2C P28335 1/20 0.39
HTR7 P34969 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
RAD52 P43351 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10096608 0.87 ALDH1A1 (0.45) KDM4EMAPTALDH1A1KMT2AKHK
SCHEMBL2879068 0.83 AURKA (0.46) KDM4EMAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL10193331 0.81 KDM4E (0.40) KDM4EGAAMAPTALDH1A1KMT2A
SCHEMBL10096609 0.80 ABL1 (0.42) KDM4EMAPTPTK2BALDH1A1KMT2A
SCHEMBL10096607 0.80 GAA (0.40) GAAMAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL2881906 0.78 KDM4E (0.41) KDM4EGAAMAPTALDH1A1KMT2A
SCHEMBL10096337 0.77 CHEK1 (0.36) KDM4EGAAMAPTGFERALDH1A1
SCHEMBL13198724 0.77 PTK2 (0.38) KDM4EGAAMAPTGFERKHK
SCHEMBL980710 0.77 GRIK2 (0.52) KDM4EMAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL2878313 0.77 ALDH1A1 (0.34) KDM4EMAPTALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-7772271-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
US-7772271-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
US-7772271-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
CN-101605758-A Methods of treating hepatitis C PTC THERAPEUTICS INC (US) 2009-12-16 CN disclosed
EP-1984332-A2 METHODS FOR TREATING HEPATITIS C PTC Therapeutics, Inc. (US) 2008-10-29 EP disclosed
US-20070299068-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 US disclosed
US-20070299068-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 US disclosed
US-20070299068-A1 Methods for treating hepatitis C PTC THERAPEUTICS, INC. 2007-12-27 US disclosed
WO-2007084413-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed
WO-2007084413-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299068-A1 Methods for treating hepatitis C HAVCR2, EIF2AK2, MAVS KDM4E 4020/4885ADRA2C 3181/4885GAA 667/4885
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS KDM4E 4020/4885ADRA2C 3181/4885GAA 667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.